Study of BAY 1817080 in the Chronic Cough
Research type
Research Study
Full title
Randomized, double-blind, parallel group, Phase 2b dose-finding, efficacy and safety study of 12-week twice daily oral administration of BAY 1817080 compared to placebo in the treatment of refractory and/or unexplained chronic cough (RUCC)
IRAS ID
278734
Contact name
Aly Hugh Morice
Contact email
Sponsor organisation
Bayer AG
Eudract number
2019-004169-42
Duration of Study in the UK
1 years, 3 months, 1 days
Research summary
Summary of Research
This Phase 2b study will evaluate three different twice daily oral doses of a selective P2X3 receptor anatagonist (BAY 1817080), and compare them to a placebo during a period of 12 weeks which would help to identify the most efficacious, tolerable and safe dose in patients suffering from refractory and/or unexplained chronic cough.
Summary of Results
Websynopsis (in technical language) & Plain Language Summary (in English): see on Bayer Clinical Trials Explorer
https://eur03.safelinks.protection.outlook.com/?url=https%3A%2F%2Fu2790089.ct.sendgrid.net%2Fls%2Fclick%3Fupn%3DXv3JSvJ-2B3M71ppf7N9agbZWluc0dOgH6w2ZqzVejRhSydh5Z20CA3Ejx79YrhCTyDLGhUjYFtYFo0o-2BFN6Bnv28s15OqYl2SWsRUPBSNrly4qw-2BYuRISGeNKZBbnowguL1Ks2AYbihig2TPzPNaMZF7xytBpMW0SlXAmEgrqsJmwvyuuaft5UYnXVEphFOQEbk2-2BXALDFtlcdfqcg-2BWsgw-3D-3D_kc-_E1aO2-2BZlVOSJJV-2FajQqskegTd6IRomHYTi-2Fbt8SH3YKjCTgniiYLI7tf7OH5esxPYkk-2BbpHn5Rzqfe8NouwmtaXGtScC74NGhOshuxFfk43igM10HfevlUEqBdVukpsRUkBMKePzPmEGJhf2nXT-2FB8rjw93L-2FEWlIujbcnlNFjlFRAsPU-2F4vKtb7OxiPZkLZhCZixmYhGKiVCrgvsB49BQ-3D-3D&data=05%7C01%7Capprovals%40hra.nhs.uk%7C1871ddcc3e794b635da708da58333a16%7C8e1f0acad87d4f20939e36243d574267%7C0%7C0%7C637919274276913456%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=opKxTIEit8dLKNq55fQ6BrtNirGdb3JUyZBqo9gDd18%3D&reserved=0
REC name
London - Harrow Research Ethics Committee
REC reference
20/LO/0346
Date of REC Opinion
27 Jul 2020
REC opinion
Further Information Favourable Opinion